Alector (ALEC) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alector (ALEC) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 34.4% versus a loss of 53.9%. Over five years, ALEC leads with a -91.3% price change compared with -93.6% for BCYC. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $225.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | BCYC |
|---|---|---|
| Share price | $2.02 | $3.81 |
| Market cap | $225.55M | $266.67M |
| 1-day change | +5.21% | +2.14% |
| YTD return | +29.49% | -46.19% |
| 1-year return | -34.42% | -53.87% |
| 5-year return | -91.33% | -93.57% |
| EPS (TTM) | $-1.09 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $9.10 |
| 52-week low | $1.09 | $3.33 |
| Distance from 52-week high | -40.59% | -58.13% |
| Analyst consensus | hold | none |
| Avg. price target upside | +63.37% | +149.34% |
| Average volume | 2.86M | 387.29K |
| Shares outstanding | 111.66M | 50.55M |
| Employees | 103 | 288 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed BCYC by 19.5 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Healthcare · Biotechnology · 103 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
ALEC vs BCYC FAQ
Which is bigger, Alector or Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $225.55M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or BCYC?
ALEC returned -34.42% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.